Brief Report
Version 1
Preserved in Portico This version is not peer-reviewed
Identification of a Low Pathogenicity Clade of SARS-CoV-2
Version 1
: Received: 28 May 2020 / Approved: 29 May 2020 / Online: 29 May 2020 (12:47:07 CEST)
How to cite: KOYAMA, T.; Parida, L. Identification of a Low Pathogenicity Clade of SARS-CoV-2. Preprints 2020, 2020050466. https://doi.org/10.20944/preprints202005.0466.v1 KOYAMA, T.; Parida, L. Identification of a Low Pathogenicity Clade of SARS-CoV-2. Preprints 2020, 2020050466. https://doi.org/10.20944/preprints202005.0466.v1
Abstract
Number of confirmed cases of COVID-19 caused by SARS-CoV-2 exceeded 5 million as of May 21, 2020. Global average of the case fatality rate of COVID-19 is about 7% so far. There exist variations in case fatality rates among countries. Particularly, Singapore and Qatar have exceptionally low case fatality rates with 0.1% while France’s rate is almost 20%. Since no magic bullet treatment for COVID-19 exists, we investigated SARS-CoV-2 strains specific to Singapore in this study to identify a clade with low pathogenicity. Variant analysis revealed that a clade with variants ORF1ab L3606F, A4489V, S2015R, T2016K, and N P13L is common in Singapore. Based on our analysis of variants and historical case statistics, the clade is dominant in a recent surge. Therefore, we suggest that low case fatality rate of Singapore possibly is attributed to the clade. Although contribution of each variant to the low pathogenicity is not clear, L3606F alone does not accomplish such low pathogenicity from the comparison with case fatality data from Japan, where L3606F is dominant. Further investigation is necessary to conclude to validate this finding.
Keywords
COVID-19; SARS-CoV-2; variant; low pathogenicity; Singapore
Subject
Biology and Life Sciences, Virology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment